» Articles » PMID: 21918551

Robust Spinal Motor Neuron Transduction Following Intrathecal Delivery of AAV9 in Pigs

Overview
Journal Gene Ther
Date 2011 Sep 16
PMID 21918551
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

Adeno-associated viral vector 9 (AAV9) has recently been shown to penetrate the blood-brain barrier via intravascular administration, making it a good candidate for diffuse gene delivery. However, the potential side effects of systemic delivery are unknown. Intrathecal viral vector administration may be more invasive than intravenous injections, but it requires far less vector and it can be performed on an outpatient basis, making it an ideal route of delivery for clinical translation. A total of 12 domestic farm pigs (<20 kg) underwent a single-level lumbar laminectomy with intrathecal catheter placement for AAV9 delivery. Animals were perfused and the tissue was harvested 30 days after treatment. Gene expression was assessed by anti-green fluorescent protein immunohistochemistry. Although a single lumbar injection resulted in gene expression limited to the lumbar segment of the spinal cord, three consecutive boluses via a temporary catheter resulted in diffuse transduction of motor neurons (MNs) throughout the cervical, thoracic and lumbar spinal cords. We now present the first successful robust transduction of MNs in the spinal cord of a large animal via intrathecal gene delivery using a self-complementary AAV9. These promising results can be translated to many MN diseases requiring diffuse gene delivery.

Citing Articles

AAV-based vectors for human diseases modeling in laboratory animals.

Aliev T, Yudkin D Front Med (Lausanne). 2025; 11:1499605.

PMID: 40007819 PMC: 11859266. DOI: 10.3389/fmed.2024.1499605.


Preclinical use of a clinically-relevant scAAV9/SUMF1 vector for the treatment of multiple sulfatase deficiency.

Presa M, Bailey R, Ray S, Bailey L, Tata S, Murphy T Commun Med (Lond). 2025; 5(1):29.

PMID: 39870870 PMC: 11772666. DOI: 10.1038/s43856-025-00734-9.


Comparative assessment of the transduction efficiency and safety associated with the delivery of AAV9-GFP vector via lumbar puncture to cynomolgus macaques with and without anti-AAV9 pre-existing antibodies.

Guibinga G, Do J, Chu B, Gu Y, Kikkawa R, Li X Mol Ther Methods Clin Dev. 2024; 32(4):101371.

PMID: 39717225 PMC: 11664412. DOI: 10.1016/j.omtm.2024.101371.


Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside.

Xu L, Yao S, Ding Y, Xie M, Feng D, Sha P J Transl Med. 2024; 22(1):866.

PMID: 39334366 PMC: 11429861. DOI: 10.1186/s12967-024-05661-2.


Recombinant Adeno-Associated Virus Vectors for Gene Therapy of the Central Nervous System: Delivery Routes and Clinical Aspects.

Slyk Z, Stachowiak N, Malecki M Biomedicines. 2024; 12(7).

PMID: 39062095 PMC: 11274884. DOI: 10.3390/biomedicines12071523.